ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,035.69
0.00%
US Tech 100
16,916.00
-0.40%
Dow Jones
37,815.92
0.00%
Brent Oil
84.975
-1.07%
Bitcoin
57,789.60
-4.64%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Zymeworks Inc (ZYME) Quote

Zymeworks Inc

Zymeworks Inc (ZYME)

NASDAQ
8.58
0.25
(3.00%)
Closed April 30 4:00PM
Delayed by 15 minutes
8.58
0.00
( 0.00% )
Pre Market: 8:00AM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
8.58
Bid
7.96
Ask
8.65
Volume
-
0.00 Day's Range 0.00
6.015 52 Week Range 13.14
Market Cap
453.754M
Previous Close
8.58
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
594,005
Shares Outstanding
70,568,222
Dividend Yield
-
PE Ratio
-3.82
Earnings Per Share (EPS)
-1.68
Revenue
76.3M
Net Profit
-118.67M

About Zymeworks Inc

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.zymeworks.com
Headquarters
North Vancouver, British Columbia, Can
Founded
1970
Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was $8.58. Over the last year, Zymeworks shares have traded in a share price range of $ 6.015 to $ 13.14.

Zymeworks currently has 70,568,222 shares outstanding. The market capitalization of Zymeworks is $453.75 million. Zymeworks has a price to earnings ratio (PE ratio) of -3.82.

ZYME Latest News

More News

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 30 2024
GlobeNewswire Inc.

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 11 2024
GlobeNewswire Inc.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 08 2024
GlobeNewswire Inc.

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

March 28 2024
GlobeNewswire Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

March 27 2024
GlobeNewswire Inc.

Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers

March 07 2024
Edgar (US Regulatory)

Form RW - Registration Withdrawal Request

March 07 2024
Edgar (US Regulatory)

Form S-3 - Registration statement under Securities Act of 1933

March 06 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.13-1.492537313438.718.717.976340388.35247351CS
4-0.62-6.739130434789.29.987.975905108.89109794CS
12-2.82-24.736842105311.413.147.9759400510.42541093CS
261.5421.8757.0413.146.8352748510.03616573CS
520.131.538461538468.4513.146.0155162998.94306076CS
1562.234.48275862076.3813.146.0156193218.77409687CS
2602.234.48275862076.3813.146.0156193218.77409687CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VRMVroom Inc
$ 16.80
(50.40%)
249
PALIPalisade Bio Inc
$ 8.90
(47.60%)
2.01M
AKANAkanda Corporation
$ 0.1305
(40.32%)
74.13M
IMCCIM Cannabis Corporation
$ 1.17
(36.05%)
11.02M
VCNXVaccinex Inc
$ 7.80
(31.31%)
71
CETXCemtrex Inc
$ 0.68
(-40.35%)
471.19k
HUBCWHub Cyber Security Ltd
$ 0.0122
(-38.69%)
45
CVRXCVRx Inc
$ 10.8499
(-30.05%)
22.43k
GVVisionary Holdings Inc
$ 0.1957
(-23.55%)
68.93k
GMMGlobal Mofy Metaverse Ltd
$ 1.18
(-20.27%)
610.63k
AKANAkanda Corporation
$ 0.1305
(40.32%)
74.13M
IMCCIM Cannabis Corporation
$ 1.17
(36.05%)
11.02M
FFIEFaraday Future Intelligent Electric Inc
$ 0.045
(2.04%)
9.28M
SQQQProShares UltraPro Short QQQ
$ 12.09
(1.17%)
4.72M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.13
(-2.40%)
3.35M

Discussion

View Full Feed
bigstocksnbonds bigstocksnbonds 4 minutes ago
I doubt it too!!
Jahvik Jahvik 4 minutes ago
https://x.com/authentichldgs/status/1785653075606163830?s=42
AHRO
SHEEPWOLF SHEEPWOLF 4 minutes ago
$SOPA: Society Pass Set to Unlock and Monetize Current and Future Subsidiary Spin-Off Opportunities Through Strong and Flexible Financing

SINGAPORE, May 01, 2024 (GLOBE NEWSWIRE) -- Society Pass Inc. (NASDAQ: SOPA) (“SoPa” or the “Company”), a leading e-commerce ecosystem in Southeast
SOPA
nidan7500 nidan7500 4 minutes ago
treden--"Dr Missling is going for prophylactic use in all 3 and more, just a matter of time."--I used to think there was a possibility of this happening---do you think we still have a chance of pulling this off plexrec...pls explain what this means . Not clear to me. THX
AVXL
dexprs dexprs 4 minutes ago
Closed XOM after several years, were bought at 45.10.
XOM
elks elks 4 minutes ago
Otc lit a bunch up at midnight. . I have another one put up dark and defunk. Peeps probably freek on that one.
NSAV
SHEEPWOLF SHEEPWOLF 4 minutes ago
$SOPA: Society Pass Set to Unlock and Monetize Current and Future Subsidiary Spin-Off Opportunities Through Strong and Flexible Financing

SINGAPORE, May 01, 2024 (GLOBE NEWSWIRE) -- Society Pass Inc. (NASDAQ: SOPA) (“SoPa” or the “Company”), a leading e-commerce ecosystem in Southeast
SOPA
Boiler_Master Boiler_Master 5 minutes ago
Company doesn't have me doing anything. I'm just an investor trying to educate some other investors bc there's so many like you who don't seem to understand the basics.

You want the company to "show you" because you're too ignorant to look at their 6 years worth of filings and see the
IQST
wisetoit wisetoit 5 minutes ago
Let me guess you’re just here to warn us all.
PSRU
Logger2 Logger2 5 minutes ago
What size of link are we looking for?
I’ve got a few that may fit !
Thanks for your help!
IFUS
QuicKtip QuicKtip 5 minutes ago
$CBDW CEO and Team are currently at the planet Micro cap showcase at booth 45 in las vegas with a demonstration of their advanced AI Chatbot https://www.youtube.com/watch?v=DdkX6vca4TY
CBDW
ALDRADJKD123 ALDRADJKD123 6 minutes ago
https://imgflip.com/i/7cou63
DJT
Hercules1 Hercules1 6 minutes ago
today is going to be a great day for the AGBA shareholders.

AGBA
Disquisition Disquisition 6 minutes ago
INCOMPREHENSIBLE DUMPING
ATXI
delerious1 delerious1 6 minutes ago
Grace Period
Dark or Defunct ❓️
IGPK
DiscoverGold DiscoverGold 6 minutes ago
Cathie Wood & Ark Invest's Buys 45,453 Shares of Palantir Technologies Inc. (PLTR)
By: Ark Invest Daily | April 30, 2024

• Cathie Wood and Ark Invest's trade activity from today 4/30.

pbs.twimg.com/media/GMdX9q7W4AANHEP?format=png&name=900x900
PLTR
LA4321 LA4321 6 minutes ago
gotta wonder what news/lack of news/rumor/funnysound will trigger the explosion ( it IS coming) ......and what direction it sends this thing.....
DUTV
Horsts Horsts 6 minutes ago
I’m just waiting for Reversesplit
SPCB
Logger2 Logger2 6 minutes ago
Do you believe they have multiple pumps or is it just one ?
Thanks for your input!
IFUS
OBE OBE 6 minutes ago
I still see the YIELD Sign. No DARK-or-DEFUNCT
heh-heh-heh...DEFUNCT whata funny word.
I wonder if it has some relationship to UNCLE as in avuncular

https://thumbs.dreamstime.com/b/educational-english-word-card-uncle-illustration-217049540.jpg
IGPK
FooBarAndGrill FooBarAndGrill 7 minutes ago
SAVA will run another Pharmacokinetics (PK) trial for patients with impaired liver function.
https://classic.clinicaltrials.gov/ct2/show/NCT06390410 A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function
SAVA
BeverlyH BeverlyH 7 minutes ago
The fearless failure can't manage to get current on the lowest, garbage, zero-accountability tier on the OTC. His solution? Tell his followers the answer lies in attempting to move up to an OTC tier with more rules, more oversight and more scrutiny. Something he's tried and failed to do for more
HHSE
Horsts Horsts 7 minutes ago
.15 today. Or lower.
SPCB
brooklyn13 brooklyn13 7 minutes ago
Well I certainly disagree. In short, Dems weren’t holding up aid to Ukraine. Nuff said.

There are self centered idiots in every aspect of governance and politics. To try to claim that it’s more prevalent in one party or another is, no offense, childish

Your Recent History

NASDAQ
ZYME
Zymeworks
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved